DYAX
Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITO... R on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.
DYAX
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1989-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.dyax.com
Total Employee:
51+
Status:
Active
Contact:
16172252501
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Amazon Route 53 DMARC AWS Global Accelerator Proofpoint Salesforce SPF
Similar Organizations
NeuroFront
Neurofront is a biotech company focused on the acquisition, development, and commercialization of transformative neuroscience medicines.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.dyax.com
- Host name: afe41c95a9e82f02c.awsglobalaccelerator.com
- IP address: 76.223.3.151
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
